Back to Feed
ClinicalTrials.gov|Clinical Trial
A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Abstract
This is a single-arm, open-label, single-center, dose-escalation Phase I platform study designed to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of an in vivo CAR-T therapy (V001 Injection, targeting BCMA, GPRC5D, DLL3,FcRH5, etc.) in patients with advanced malignant tumors. Phase: EARLY_PHASE1 Status: RECRUITING Conditions: Advanced Malignant Tumours Interventions: V001-BCMA; V001-GPRC5D; V001-DLL3; V001-FcRH5
Keywords
Advanced Malignant Tumours